Becton, Dickinson and Company (NYSE:BDX) Research Coverage Started at Wolfe Research

Wolfe Research assumed coverage on shares of Becton, Dickinson and Company (NYSE:BDX) in a research note issued to investors on Tuesday morning, MarketBeat.com reports. The brokerage issued an outperform rating on the medical instruments supplier’s stock.

Several other research firms have also recently commented on BDX. Evercore set a $180.00 target price on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. Weiss Ratings upgraded shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 28th. TD Cowen boosted their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Piper Sandler upped their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Finally, Bank of America upped their price objective on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Monday, August 31st. Eight investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus target price of $185.07.

Becton, Dickinson and Company Stock Up 3.0%

Shares of BDX stock opened at $200.21 on Tuesday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $200.47. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The firm has a market cap of $55.16 billion, a PE ratio of 14.95, a price-to-earnings-growth ratio of 13.10 and a beta of 0.21. The stock has a 50 day moving average of $185.10 and a 200-day moving average of $164.86.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were given a dividend of $1.05 per share. The ex-dividend date was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. This represents a 0.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 6,906 shares of company stock worth $1,265,855. 0.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Maryland Capital Advisors Inc. increased its stake in Becton, Dickinson and Company by 13,900.0% in the third quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 139 shares during the period. SHP Wealth Management acquired a new position in Becton, Dickinson and Company in the fourth quarter worth about $26,000. Meeder Asset Management Inc. lifted its stake in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares during the period. Main Street Group LTD bought a new position in Becton, Dickinson and Company during the first quarter worth about $29,000. Finally, Bell Investment Advisors Inc acquired a new stake in Becton, Dickinson and Company during the second quarter valued at approximately $29,000. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.